Cairo: Chairman of the Egyptian Drug Authority (EDA) Ali el Ghamrawy emphasized that the authority adopts an approach based on continuous dialogue and effective cooperation with various industry partners to support the sustainable development of the pharmaceutical sector and enhance the Egyptian market's readiness for global changes and foreign expansion.

According to State Information Service Egypt, this announcement was made during an AmCham roundtable attended by AmCham CEO Sylvia Menassa and several executives from international and local pharmaceutical firms. Ghamrawy stated that the EDA's priorities include balancing industry support with the provision of safe, high-quality medicines for citizens, while also developing regulations aimed at attracting investment and boosting global confidence in the Egyptian market.

He further highlighted the EDA's efforts to expand its presence in Africa by facilitating the registration process and establishing mutual recognition agreements with regional regulators to increase exports. Participants at the roundtable praised the EDA for its regulatory improvements, noting that enhanced transparency and streamlined procedures are strengthening market competitiveness and fostering joint cooperation.

Discussions during the meeting focused on supporting the national industry and implementing policies to position Egypt as a regional pharmaceutical manufacturing and export hub. Attendees emphasized the importance of continued coordination between the EDA and its partners to ensure a sustainable and attractive investment environment.

The meeting aligns with the EDA's strategy to integrate with industry partners and upgrade regulatory systems in accordance with international quality standards.